MAP2K2(MEK2)
Sign in to save this workspaceUniProt P36507 · PDB · AlphaFold · Substrate: ERK(K52R) · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Vemurafenib | 98.1% | 1.9% | 96.49 | 0.598 |
| 2 | Bosutinib | 95.4% | 4.6% | 87.22 | 0.555 |
| 3 | Neratinib | 93.2% | 6.8% | 93.18 | 0.597 |
| 4 | Trametinib | 93.1% | 6.9% | 99.50 | 0.718 |
| 5 | Gilteritinib | 91.7% | 8.3% | 88.97 | 0.506 |
| 6 | Zanubrutinib | 89.9% | 10.1% | 98.24 | 0.788 |
| 7 | Pirtobrutinib | 89.3% | 10.7% | 99.49 | 0.656 |
| 8 | Sunitinib | 88.5% | 11.5% | 91.73 | 0.524 |
| 9 | Cabozantinib | 78.4% | 21.6% | 92.73 | 0.751 |
| 10 | Tivozanib | 74.5% | 25.5% | 92.42 | 0.673 |
| 11 | Ripretinib | 66.0% | 34.0% | 92.95 | 0.674 |
| 12 | Cobimetinib | 59.8% | 40.2% | 100.00 | 0.644 |
| 13 | Ceritinib | 53.0% | 47.0% | 95.44 | 0.618 |
| 14 | Ibrutinib | 49.2% | 50.8% | 94.74 | 0.723 |
| 15 | Canertinib | 47.3% | 52.7% | 96.49 | 0.671 |
| 16 | Capivasertib | 46.3% | 53.7% | 96.48 | 0.644 |
| 17 | Nintedanib | 44.4% | 55.6% | 90.23 | 0.608 |
| 18 | Binimetinib | 43.5% | 56.5% | 100.00 | 0.689 |
| 19 | Dasatinib | 43.4% | 56.6% | 87.97 | 0.699 |
| 20 | Pacritinib | 41.9% | 58.1% | 88.64 | 0.452 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 6.54
- Epithelial log2(TPM+1): 6.20
- Fold change: 0.34
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K2
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…